AMRX as reported
Amneal Pharmaceuticals, Inc. reported $3.05B of revenue over the trailing twelve months, +7.6% on the year before. 11 reported series are charted on this page, each one as filed.
$3.05B
Revenue, trailing twelve months · to Q1 2026 · +7.6% against the twelve months before
- Net Income
- $122M
Net Income · −1036% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $241M
Free Cash Flow · −4.1% year on year · trailing twelve months to Q1 2026
- Op Margin
- 14%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.05B | +7.6% | Q1 2026 |
| Net Income | $122M | −1036% | Q1 2026 |
| EPS | $0.38 | −1050% | Q1 2026 |
| Gross Margin | 39% | n/a | Q1 2026 |
| Op Margin | 14% | n/a | Q1 2026 |
| Net Margin | 4.1% | n/a | Q1 2026 |
| ROE | −95% | n/a | Q1 2026 |
| ROA | 1.4% | n/a | Q1 2026 |
| ROIC | 14% | n/a | Q1 2026 |
| Free Cash Flow | $241M | −4.1% | Q1 2026 |
| P/E | 47.3 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Amneal Pharmaceuticals, Inc. (AMRX) - Revenue & ProfitRevenue & ProfitAmneal Pharmaceuticals, Inc. (AMRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #22 of 28 by Smart Score